Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2011

View Archived Issues

Ampio and Daewoong enter urology drug agreement in South Korea

Diffusion tensor imaging detects cerebral anomalies in patients with Asperger's syndrome

Novel PET tracer may help guide development of fatty-acid amide hydrolase inhibitors

MedImmune presents new safety data on MEDI-573 in breast cancer

Synthesis and preclinical testing of novel histamine H3 receptor antagonists described

Repros completes enrollment in three ongoing Androxal trials

First-in-human study supports feasibility of intraoperative tumor-specific fluorescence imaging

Novel susceptibility gene for major depression identified

Randomized, double-blind trial assesses LY-2189265 as monotherapy for type 2 diabetes

BioLineRx reports preliminary first-in-human data on BL-1021

Nanobiotix's lead product enters clinic

Compugen validates immunomodulating fusion proteins in in vivo models of autoimmune diseases

GlaxoSmithKline discloses new fatty acid synthase inhibitors

Spanish research center prepares novel protein kinase inhibitors

Viamet Pharmaceuticals begins first-in-human trial of VT-1161

Novartis synthesizes novel cyclin-dependent kinase inhibitors

Rare Disease Therapeutics selects distributor for Anascorp

Avila Therapeutics advances phase Ib AVL-292 study

ProFibrix completes recruitment in two phase II Fibrocaps trials

Scientists at Medivation claim new neurotransmitter receptor modulators

Oncothyreon obtains license to anticancer agents from Sanford-Burnham Medical Research Institute

Arrien gathers financing to support advancement of small-molecule protein kinase inhibitors

Eisai enters collaboration with SFJ to conduct phase III E-7080 trials

Thrasos Innovation advances THR-184 to clinic

Astellas Pharma set to launch Betanis in Japan

Vibativ approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...